Readers are directed to the PDF version of this article.
Publisher’s note: This guidance has been reviewed in 2020 and is considered to be out of date. Up-to-date guidance, including an algorithm for testing, can be found in this consensus statement.
Results of SOUL trial suggest oral semaglutide offers similar cardiovascular benefits to the injectable formulation.
22 Apr 2025